Therefore, the study was aimed to examine the effect of CAB vs. GnRH agonist monotherapy on BMD change and to determine the underlying factors affecting BMD during 12 months post-treatment initiation in prostate cancer patients and the 10-year probability of major fractures. This evidence concerns the gene GNRH1 and prostate cancer.